Supporting Data
TransIT®-EE Solution Leads to Enhanced Luciferase Expression in the Liver. TransIT®-QR or TransIT®-EE Delivery Solutions were used to deliver 10 µg of a luciferase expression vector to mice using the hydrodynamic delivery tail vein injection procedure. Twenty-four hours post-injection the livers were harvested and assayed for luciferase activity.
TransIT®-EE Solution Leads to Enhanced Luciferase Expression in a Variety of Organs. TransIT®-QR or TransIT®-EE Delivery Solutions were used to deliver 10 µg of pCI-Luc (CMV promoter-driven luciferase expression vector) to mice using the hydrodynamic tail vein injection procedure. Twenty-four hours post-injection the organs were harvested and assayed for luciferase activity.
NOTE: Following gene delivery via a tail vein injection, the highest level of transgene expression is found in the liver, with reduced levels of expression found in the spleen, lung, heart and kidneys.
Resources
Specifications
Storage Conditions
All Configurations: Store at 4°C
Product Guarantee
All Configurations: 1 year
Usage Statement
All Configurations: For Research Use Only.
Animal Origin Statement
All Configurations: This product is animal origin free.
Technical Product Literature
Full Protocols
TransIT®-EE Delivery Solution Full Transfection Protocol (PDF)
SDS
TransIT®-EE Delivery Solution SDS (PDF)